80 related articles for article (PubMed ID: 9884357)
1. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.
Boyer JD; Chattergoon MA; Ugen KE; Shah A; Bennett M; Cohen A; Nyland S; Lacy KE; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
Clin Immunol; 1999 Jan; 90(1):100-7. PubMed ID: 9884357
[TBL] [Abstract][Full Text] [Related]
2. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.
MacGregor RR; Boyer JD; Ugen KE; Lacy KE; Gluckman SJ; Bagarazzi ML; Chattergoon MA; Baine Y; Higgins TJ; Ciccarelli RB; Coney LR; Ginsberg RS; Weiner DB
J Infect Dis; 1998 Jul; 178(1):92-100. PubMed ID: 9652427
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.
Boyer JD; Cohen AD; Vogt S; Schumann K; Nath B; Ahn L; Lacy K; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
J Infect Dis; 2000 Feb; 181(2):476-83. PubMed ID: 10669329
[TBL] [Abstract][Full Text] [Related]
4. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".
MacGregor RR; Boyer JD; Ugen KE; Tebas P; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; Weiner DB
Vaccine; 2005 Mar; 23(17-18):2066-73. PubMed ID: 15755572
[TBL] [Abstract][Full Text] [Related]
5. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
[TBL] [Abstract][Full Text] [Related]
8. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.
Lu Y; Xin KQ; Hamajima K; Tsuji T; Aoki I; Yang J; Sasaki S; Fukushima J; Yoshimura T; Toda S; Okada E; Okuda K
Clin Exp Immunol; 1999 Feb; 115(2):335-41. PubMed ID: 9933462
[TBL] [Abstract][Full Text] [Related]
9. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
10. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment.
Ye P; Kazanjian P; Kunkel SL; Kirschner DE
J Lab Clin Med; 2004 May; 143(5):310-9. PubMed ID: 15122175
[TBL] [Abstract][Full Text] [Related]
11. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
[TBL] [Abstract][Full Text] [Related]
12. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
[TBL] [Abstract][Full Text] [Related]
14. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
[TBL] [Abstract][Full Text] [Related]
16. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
Kelleher AD; Puls RL; Bebbington M; Boyle D; Ffrench R; Kent SJ; Kippax S; Purcell DF; Thomson S; Wand H; Cooper DA; Emery S
AIDS; 2006 Jan; 20(2):294-7. PubMed ID: 16511428
[TBL] [Abstract][Full Text] [Related]
19. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
20. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
